# Study of INCB053914 in Subjects With Advanced Malignancies

> **NCT02587598** · PHASE1,PHASE2 · TERMINATED · sponsor: **Incyte Corporation** · enrollment: 97 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** INCB053914
- **DRUG:** I-DAC (Intermediate dose cytarabine)
- **DRUG:** Azacitidine
- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT02587598
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-12-29
- **Primary completion:** 2020-08-11
- **Final completion:** 2020-08-11
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2021-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02587598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02587598, "Study of INCB053914 in Subjects With Advanced Malignancies". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02587598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*